"I think he'll strip the company down to its bare bones and act very much like a private-equity firm," said analyst David Lickrish, who covers Biovail for New York City-based Broadpoint Capital Inc. "But that doesn't address the broader issue of developing Biovail's drug pipeline."
No comments:
Post a Comment